What are the effects of immunoglobulins for hospitalized infants with respiratory syncytial virus (RSV) infection?

Abstract

For hospitalized infants with RSV infection, low‐certainty evidence suggests that immunoglobulins (motavizumab or palivizumab) may result in unimportant absolute differences in mortality and few to no differences in length of hospitalization, need for and duration of mechanical ventilation, need for and duration of supplemental oxygen, need for intensive care unit (ICU) admission, or any adverse events. However, the number of participants included in most analyses was insufficient to yield reliable results.